Editas Medicine Receives EMA’s Orphan Medicinal Product … – Markets Insider
Press Telegraph |
Editas Medicine Receives EMA's Orphan Medicinal Product …
Markets Insider CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the … Editas Medicine, Inc. (NASDAQ:EDIT) Moving Today – Down $0.85 |
